Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors
- 3.3k Downloads
Identification and comprehensive care of individuals who have Fabry disease (FD) requires a multidisciplinary approach inclusive of genetic testing, test interpretation, genetic counseling, long term disease symptom monitoring, treatment recommendations, and coordination of therapy. The purpose of this document is to provide health care professionals with guidelines for testing, care coordination, identification of psychosocial issues, and to facilitate a better understanding of disease treatment expert recommendations for patients with Fabry disease. These recommendations are the opinions of a multicenter working group of genetic counselors, medical geneticists, and other health professionals with expertise in Fabry disease counseling, as well as representatives/founders of the two United States based Fabry disease patient advocacy groups who are themselves affected by Fabry disease. The recommendations are U.S. Preventive Task Force Class III, and they are based on clinical experience, a review of pertinent English-language articles, and reports of expert committees. This document reviews the genetics of Fabry disease, the indications for genetic testing, interpretation of results, psychosocial considerations, and references to professional and patient resources.
KeywordsFabry disease Enzyme replacement therapy Genetic counseling Newborn screening Lysosomal storage diseases
The authors of the paper would like to thank the Fabry patients and family members who teach us as we work together to learn more about Fabry disease.
The Fabry Support and Information Group (FSIG) has received donations from Genzyme Corporation (the manufacturer of Fabrazyme®, a drug referenced in these guidelines), Shire Human Genetic Therapies, Inc. (the manufacturer of Replagal®, a drug referenced in these guidelines), and Amicus Therapeutics. The National Fabry Disease Foundation has received donations from Genzyme Corporation, Shire Human Genetic Therapies and Amicus Therapeutics. The authors and reviewers of this paper volunteered their time, and did not receive an honorarium.
The practice guidelines of the National Society of Genetic Counselors (NSGC) are developed by members of the NSGC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns; including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the NSGC practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are only current as of their publication date, and are subject to change without notice as advances emerge.
In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider’s best medical judgment based on the clinical circumstances of a particular patient or patient population. Practice guidelines are published by NSGC for educational and informational purposes only, and NSGC does not “approve” or “endorse” any specific methods, practices, or sources of information.
- Bennett, R. L. (2010b). Genetic counseling and psychosocial issues for individuals and their families with Fabry disease. In Elstein D, Altarescu G, Beck M (Eds.), Fabry disease. New York: Springer.Google Scholar
- Brower, A., Hoffman, A. J., Thompson, B. H, & Watson, M. S. (2011). Utilization of the newborn screening translational research network to advance research and clinical applications in lysosomal storage disorders. 7th WORLD symposium 2011.Google Scholar
- Clarke, A. (Ed.). (1998). The genetic testing of children. Oxford: BIOS Scientific.Google Scholar
- Desnick, R., & Ioannou, Y., (2006). Eng C. α-Galactosidase A deficiency: Fabry disease. In: Valle D, Baudette A, Vogelstein KC, (Eds.), The online metabolic & molecular bases of inherited disease. McGraw-Hill Companies Inc. www.ommbid.com, accessed Mar 2011.
- Dink, A., Sims, I., Pay, S., Calgary, K., & Can, C. (2000). Fabry’s disease mimicking familial Mediterranean fever. Clinical and Experimental Rheumatic, 18, 787–788.Google Scholar
- Elstein, D., Altars, G., & Beck, M. (ends) (2010). Fabry disease, Springer.Google Scholar
- Laney, D.A., Gruskin, D.J., Fernhoff, P.M., Cubells, J.F., Ousley, O.Y., Hipp, H., et al. (2010). Social-adaptive and psychological functioning of patients affected by fabry disease. Journal of Inherited Metabolic Disease. Online.Google Scholar
- Lidov, O., West, M., Pintos-Morell, G., et al. (2010). Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature. Genetics in Medicine, 12(11).Google Scholar
- Mehta, A., Beck, M., & Sunder-Plassmann, G. (Eds.). (2006). Fabry disease: Perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis.Google Scholar
- National Society of Genetic Counselors. (1995). National Society of Genetic Counselors, Position statement on prenatal and childhood testing for adult-onset disorders. Perspectives Genetic Counseling, 17, 5.Google Scholar
- Ortiz, A., Oliveira, J. P., Waldek, S., Warnock, D. G., Cianciaruso, B., Wanner, C., et al. (2008a). Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrology, Dialysis, Transplantation, 23, 1600–1607.PubMedCrossRefGoogle Scholar
- Resta, R. G. (Ed.). (2000). Psyche and helix, Psychological aspects of genetic counseling. Essays by Seymour Kessler, PhD. New York: Wiley-Liss.Google Scholar
- Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., et al. (2000). Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. PNAS, 97, 365–370.Google Scholar
- Scott, C. R., Elliot, S., Glass, M., Buroker, N., Thomas, L., Keutzer, J., et al. (2011). Gelb MH (2011) Application of a triplex assay by MS/MS for the detection of Fabry, Pompe, and MPS-I within a newborn screening laboratory. 7th WORLD symposiumGoogle Scholar
- Uhlmann, W. R., Schuette, J. L., & Yashar, B. (2009). A guide to genetic counseling (2nd ed.). Hoboken: Wiley Blackwell.Google Scholar
- Wang, R. Y., Bodamer, O. A., Watson, M. S., Wilcox, W. R., & on behalf of the ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. (2011). Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genetics in Medicine, 13(5), 457–484.PubMedCrossRefGoogle Scholar
- Watt, T., Burlina, A. P., Cazzorla, C., Schönfeld, D., Banikazemi, M., Hopkin, R. J., et al. (2010). Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genetics in Medicine, 12(11), 703–712.PubMedCrossRefGoogle Scholar
- Weil, J. (2000). Psychosocial genetic counseling. Oxford: Oxford University Press.Google Scholar
- Wise, D., Wallace, H. F., & Jellinek, E. H. (1962). Angiokeratoma corporis diffusum. Oxford Journals Medicine New Series, XXXI(122), 177–212.Google Scholar